Human Microbiome Therapeutics Market: Global Market Size, Forecast, Insights, Segmentation, and Competitive Landscape with Impact of COVID-19 & Russia-Ukraine War

The global human microbiome therapeutics market is expected to grow at a CAGR of around 23.6% during 2024-2033. This report on global human microbiome therapeutics market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape. The report presents a clear picture of the global human microbiome therapeutics market by segmenting the market based on technology, type, therapeutic area, and region. Also, detailed profiles of companies operating in the human microbiome therapeutics market are provided in this report. We believe that this report will aid the professionals and industry stakeholders in making informed decision.

 

 

Market Drivers

The market for human microbiome therapeutics is witnessing substantial expansion, primarily propelled by the rising prevalence of conditions linked to dysbiosis within the gut microbiota. Furthermore, significant investment in biological drug discovery and research is serving as a catalyst for this growth. There is an increasing need for accurate, reliable, and timely treatments to manage conditions such as hepatic encephalopathy, phenylketonuria, C. difficile infection, and multidrug-resistant urinary tract infections. This surge in global demand is anticipated to play a pivotal role in driving market expansion.

 

Market Restraints

Government regulations require thorough testing and clinical trials to establish the safety and efficacy of microbiome therapeutics before they receive approval for patient use. This process involves evaluating the potential risks associated with introducing microbial products into the body and assessing their effectiveness in treating specific conditions. Further, comprehending the nuanced interactions within the human microbiome and its impact on health and disease poses a substantial challenge. The intricate nature of microbial communities, coupled with their dynamic behavior, necessitates the use of advanced research methodologies and analytical tools.

 

Market Opportunities

Furthermore, North America boasts a well-established healthcare infrastructure and robust regulatory framework, laying a solid foundation for the flourishing of human microbiome therapeutics in the region. The prevalence of chronic diseases further augments this fertile ground for growth. Key market players and biotechnology firms committed to microbiome research play a pivotal role in driving the expansion of the market. Their concerted efforts not only fuel innovation but also facilitate the commercialization of microbiome-based therapies, thereby propelling the sector forward.

 

Recent Industry Development 

• In April 2023, regulatory authorities in the United States granted approval for Vowst, a medication derived from human feces, to address C. difficile infection.

• In September 2022, researchers at Stanford University achieved a significant breakthrough by creating a synthetic microbiome comprising more than 100 bacterial species.

 

Historical & Forecast Period

Base Year: 2023

Historical Period: 2019-2023

Forecast Period: 2024-2033

Report’s Unit: US$

 

Global Human Microbiome Therapeutics Market Segmentation

Market by Technology

• Genomics
• Proteomics
• Metabolomics

Market by Therapeutic Area

• Gastrointestinal Disorders
• Infectious Diseases
• Dermatological Indications
• Cancers
• Metabolic Disorders

Market by Type

• Gastrointestinal Disorders
• Probiotics and Prebiotics
• Medical Food
• Diagnostic Tests

Market by Region

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe

North America

• United States
• Canada

Asia Pacific

• China
• Japan
• India
• South Korea
• Australia
• ASEAN
• Rest of Asia Pacific

Latin America

• Mexico
• Brazil
• Argentina
• Chile
• Rest of Latin America

Middle East & Africa

• Saudi Arabia
• Turkey
• Iran
• United Arab Emirates
• Rest of Middle East & Africa

List of Mentioned Companies

• Bristol-Myers Squibb
• Dow Inc Chemical
• DuPont de Nemours, Inc.
• Evelo Biosciences, Inc.
• Johnson & Johnson
• Kaleido Biosciences, Inc.
• Merck & Co. Inc.
• Pfizer Inc.
• PureTech Health PLC
• Seres Therapeutics, Inc.
• Takeda Pharmaceutical Company Limited
• Vertex Pharmaceuticals

 

Report Coverage

Report Feature	Details
Base Year	2023
Historical Period	2019-2022
Forecast Period	2024-2033
Units	US$ Million
Segments Covered	Technology,  Therapeutic Area, Type, Region
Region Covered	Europe, North America, Asia Pacific, Latin America, Middle East and Africa
Companies Covered	Astranate Sp. z o.o, CollMot Entertainment, Drone Arrival, Inc., Drone Light Show Company, Dronisos, Geoscan, Guangzhou Ehang Intelligent Technology Co. Ltd, Intel Corporation, Pixis Drones, Shenzhen DAMODA Intelligent Control Technology Co., Shenzhen HighGreat Innovation Technology Development Co., Ltd, Sky Elements, LLC, Skymagic, SPH Engineering Limited, Verge Aero.
Purchase Options	Single User License: US$ 2,999 Five User License: US$ 3,499 Corporate License: US$ 4,499

 

Research Methodology

During the course of the research study, we conducted extensive primary and secondary research. The research commenced with extensive exploration through secondary sources followed by primary research. With these research methods, we were able to estimate the market size, to identify the factors that promote the growth in this market as well as the factors that hamper the growth in the market.

Comprehensive primary and secondary methods helped us to identify the trends in the market and to project the opportunities that the key players may get during the forecast period. Apart from these approaches, various analytical and statistical approaches were also used during data extraction cleaning, and analysis. 

Post-secondary & primary research, we conducted expert interviews to validate all the information we collected during the course of the study. So, a blend of these three-way approaches helped us in data triangulation and to provide an accurate market scenario in our report.

 

Key Questions Answered in the Report

• What will be the global human microbiome therapeutics market size and the growth rate in the coming year?
• What are the main key factors driving the market?
• What are the key market trends impacting the growth of the market?
• What are the market opportunities and threats in the market?
• What industrial trends, drivers, and challenges are manipulating its growth?
• Which are trending factors influencing the market shares of the top regions across the globe?
• Who are the key market players in the industry?
• What is the impact of Covid19 on the current industry?

1. Preface
1.1 Objective
1.2 Target Audience & Key Offerings
1.3 Report’s Scope
1.4 Research Methodology
1.4.1 Phase I
1.4.2 Phase II
1.4.3 Phase III
1.5 Assumptions
2. Key Insights
2.1. Global Market in 2023
2.2. Impact of COVID-19
2.3. Growth Opportunities and Challenges
2.4. Key Industry Trends
3. Global Human Microbiome Therapeutics Market Dynamics
3.1. Introduction
3.2. Market DROs
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Industry Trends
3.4. SWOT Analysis
3.5. Market Value Chain Analysis
3.6. Porter’s Five Forces Analysis
3.7. PESTLE Analysis
3.8. Key Price Indicators
3.9. Ansoff Matrix
3.10. Government Laws and Industry Regulations
4. Global Human Microbiome Therapeutics Market Analysis
4.1. Market Portraiture
4.2. Market Size (US$ Million, 2019-2023)
4.3. Market Forecast (US$ Million, 2024-2033)
4.4. Impact of COVID-19
4.5. Impact of Russia-Ukraine War
5. Global Human Microbiome Therapeutics Market by Technology (US$ Million, 2019-2033)
5.1. Introduction
5.2. Genomics
5.3. Proteomics
5.4. Metabolomics
5.5. Key Segment Investment Opportunity
6. Global Human Microbiome Therapeutics Market by Therapeutic Area (US$ Million, 2019-2033)
6.1. Introduction
6.2. Gastrointestinal Disorders
6.3. Infectious Diseases
6.4. Dermatological Indications
6.5. Cancers
6.6. Metabolic Disorders
6.7. Others
6.8. Key Segment Investment Opportunity
7. Global Human Microbiome Therapeutics Market by Type (US$ Million, 2019-2033)
7.1. Introduction
7.2. Probiotics and Prebiotics
7.3. Medical Food
7.4. Diagnostic Tests
7.5. Others
7.6. Key Segment Investment Opportunity
8. Global Human Microbiome Therapeutics Market by Region (US$ Million, 2019-2033)
8.1. Introduction
8.2. Europe
8.3. North America
8.4. Asia Pacific
8.5. Latin America
8.6. Middle East & Africa
8.7. Key Segment Investment Opportunity
9. Europe Human Microbiome Therapeutics Market (US$ Million, 2019-2033)
9.1. Introduction
9.2. Key Drivers and Takeaways
9.3. Europe Market Breakup by Technology
9.4. Europe Market Breakup by Therapeutic Area
9.5. Europe Market Breakup by Type
9.6. Europe Market Breakup by Country
9.6.1. Germany
9.6.2. United Kingdom
9.6.3. France
9.6.4. Italy
9.6.5. Spain
9.6.6. Russia
9.6.7. Netherlands
9.6.8. Sweden
9.6.9. Poland
9.6.10. Rest of Europe
10. North America Human Microbiome Therapeutics Market (US$ Million, 2019-2033)
10.1. Introduction
10.2. Key Drivers and Takeaways
10.3. North America Market Breakup by Technology
10.4. North America Market Breakup by Therapeutic Area
10.5. North America Market Breakup by Type
10.6. North America Market Breakup by Country
10.6.1. United States
10.6.2. Canada
11. Asia Pacific Human Microbiome Therapeutics Market (US$ Million, 2019-2033)
11.1. Introduction
11.2. Key Drivers and Takeaways
11.3. Asia Pacific Market Breakup by Technology
11.4. Asia Pacific Market Breakup by Therapeutic Area
11.5. Asia Pacific Market Breakup by Type
11.6. Asia Pacific Market Breakup by Country
11.6.1. China
11.6.2. Japan
11.6.3. India
11.6.4. South Korea
11.6.5. Australia
11.6.6. ASEAN
11.6.7. Rest of Asia Pacific
12. Latin America Human Microbiome Therapeutics Market (US$ Million, 2019-2033)
12.1. Introduction
12.2. Key Drivers and Takeaways
12.3. Latin America Market Breakup by Technology
12.4. Latin America Market Breakup by Therapeutic Area
12.5. Latin America Market Breakup by Type
12.6. Latin America Market Breakup by Country
12.6.1. Mexico
12.6.2. Brazil
12.6.3. Argentina
12.6.4. Chile
12.6.5. Rest of Latin America
13. Middle East and Africa Human Microbiome Therapeutics Market (US$ Million, 2019-2033)
13.1. Introduction
13.2. Key Drivers and Takeaways
13.3. Middle East and Africa Market Breakup by Technology
13.4. Middle East and Africa Market Breakup by Therapeutic Area
13.5. Middle East and Africa Market Breakup by Type
13.6. Middle East and Africa Market Breakup by Country
13.6.1. Saudi Arabia
13.6.2. Turkey
13.6.3. Iran
13.6.4. United Arab Emirates
13.6.5. Rest of Middle East & Africa
14. Competitive Landscape
14.1. Competitive Dashboard
14.2. Key Industry Strategies Analysis
14.3. Recent Developments
14.4. Market Scenario
15. Company Profiles
15.1. Bristol-Myers Squibb
15.2. Dow Inc Chemical
15.3. DuPont de Nemours, Inc.
15.4. Evelo Biosciences, Inc.
15.5. Johnson & Johnson
15.6. Kaleido Biosciences, Inc.
15.7. Merck & Co. Inc.
15.8. Pfizer Inc.
15.9. PureTech Health PLC
15.10. Seres Therapeutics, Inc.
15.11. Takeda Pharmaceutical Company Limited
15.12. Vertex Pharmaceuticals